Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Kiffer, Carlos R V ^a   Pignatari, Antonio C C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BRAZIL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MORAXELLA CATARRHALIS; NONHUMAN; PHARMACODYNAMICS; PRESCRIPTION; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; ADOLESCENT; ADULT; AGED; DRUG EFFECT; FEMALE; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 80054854410     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-286     Document Type: Article

References (32)

1. World Health Organization Department of Communicable Disease Surveillance and Response. WHO Global Strategy for Containment of Antimicrobial Resistance (WHO/CDS/CSR/DRS/2001.2). 2001, 1-96. WHO, Switzerland, World Health Organization., http://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_DRS_2001_2_EN/en/
2. Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Rose D, Leinonen M, Saikku P. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001, 56:296-301. 10.1136/thorax.56.4.296, 1746017, 11254821.
3. Austrian R. Pneumococcus: the first one hundred years. Rev Infect Dis 1981, 3:183-9. 10.1093/clinids/3.2.183, 7020040.
4. Goldblatt D. Recent developments in bacterial conjugates vaccines. J Med Microbiol 1998, 47:563-7. 10.1099/00222615-47-7-563, 9839559.
5. Zettler EW, Scheibe RM, Dias CAG, Santafe P, Moreira JS, Santos DS, Fritscher CC. Polymerase chain reaction used to detect Streptococcus pneumoniae resistance to penicillin. J Bras Pneumol 2004, 30(6):521-27.
6. Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors and prognosis. Rev Infect Dis 1985, 7:133-42. 10.1093/clinids/7.2.133, 3890093.
7. Butler JC, Dowel SF, Breiman RF. Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Vaccine 1998, 16:1693-7. 10.1016/S0264-410X(98)00132-7, 9778743.
8. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009, 49(1):124-31. 10.1086/599375, 19480579.
9. Infectious Disease Society of America Bad bugs, no drugs, as antibiotic discovery stagnates, a public health crisis brews, July 2004. Infectious Disease Society of America., http://www.medicalnewstoday.com/medicalnews.php?newsid=11084
10. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003, 11:982-92.
11. Barbour A, Scaglione F, Derendorf H. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents 2010, 35(5):431-8. 10.1016/j.ijantimicag.2010.01.023, 20219329.
12. AAP Subcommittee on Management of Sinusitis, AAP Committee on Quality Improvement Clinical practice guideline: management of sinusitis. Pediatrics 2001, 108(3):798-808. AAP Subcommittee on Management of Sinusitis, AAP Committee on Quality Improvement.
13. Sinus and Allergy Health Partnership Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngology-Head Neck Surg 2004, 130(1):1-45. Sinus and Allergy Health Partnership.
14. AAP and AAFP Subcommittee on Management of Acute Otitis Media Clinical practice guideline: diagnosis and management of acute otitis media. Pediatrics 2004, 113(5):1451-65. AAP and AAFP Subcommittee on Management of Acute Otitis Media.
15. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: twentieth informational supplement M100-S20. 2010, CLSI, Wayne, Pa, Clinical and Laboratory Standards Institute.
16. Spyker DA, Rugloski RJ, Vann RI, O'Brien WM. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother 1977, 11(1):132-141. 351932, 836010.
17. Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen JD, Sharma A. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 2007, 51(1):103-109. 10.1128/AAC.00852-06, 1797671, 17060516.
18. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997, 41(10):2256-2260. 164102, 9333057.
19. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998, 42(8):2060-2065. 105860, 9687407.
20. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R, Uchida H. Single- and multiple-dose pharmacokinetics of am-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995, 39(12):2635-2640. 163003, 8592993.
21. Korzeniowski OM, Scheld WM, Sande MA. Comparative pharmacology of cefaclor and cephalexin. Antimicrob Agents Chemother 1977, 12(2):157-162. 429879, 900915.
22. Burgess DS, Frei CR, Lewis JS, Fiebelkorn KS, Jorgensen JH. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitides. Clin Microbiol Infect 2007, 13:33-39. 10.1111/j.1469-0691.2006.01617.x, 17184285.
23. Alou L, Aguilar D, Sevillano D, Gimenez MJ, Gonzalez N, Echevarria O, Torrico M, Martin JE, Valdes L, Prieto J. Levofloxacin vs azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid. J Chem 2007, 19(6):670-672.
24. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001, 45:2793-2797. 10.1128/AAC.45.10.2793-2797.2001, 90733, 11557471.
25. Mendes C, Kiffer CRV, Blosser-Middleton RS, Jones ME, Karlowsky JA, Barth A, Rossi F, Andrade S, Sader HS, Thornsberry C, Sahm DF. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens--a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002. Clin Microbiol Infect 2004, 10:521-526. 10.1111/j.1469-0691.2004.00870.x, 15191379.
26. Castañeda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, Brandão AP, Maldonado A, Hormazabal JC, Martínez IT, Llanes R, Sánchez J, Feris JM, Echaniz-Aviles G, Carnalla-Barajas MN, Terrazas MG, Monroy IH, Chamorro G, Weiler N, Camou T, Gabarrot GG, Spadola E, Payares D, Gabastou JM, Di Fabio JL, de la Hoz F, . SIREVA II Group Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 2009, 28(9):265-70. SIREVA II Group.
27. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GC, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infect Dis 2007, 44:S27-72.
28. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med 2001, 111(Suppl 9A):13S-18S.
29. Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004, 24(5):479-84. 10.1016/j.ijantimicag.2004.06.010, 15519481.
30. Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005, 26(2):120-5. 10.1016/j.ijantimicag.2005.04.012, 16046101.
31. Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Antimicrobial resistance rate epidemiology study team program. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003, 47(1):292-6. 10.1128/AAC.47.1.292-296.2003, 149036, 12499204.
32. Pichichero ME, Doern GV, Kuti JL, Nicolau DP. Probability of achieving requisite pharmacodynamic exposure for oral β-lactam regimens against Haemophilus influenzae in Children. Pediatr Drugs 2008, 10(6):1-7.